The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
TILs across solid tumors: challenges, targets, and future directions
Allison Betof Warner, MD, Stanford Medicine, Stanford, CA, and Ben Creelan, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, discuss the evolving landscape of tumor-infiltrating lymphocytes (TILs) and other cell therapies across solid tumors, focusing on melanoma and lung cancer. The rountable highlights genetically edited TILs, membrane-bound IL-15, TCRs, and CARs. They explore efforts to reduce IL-2-related toxicity, challenges of HLA loss, and the promise of one-time therapies over ongoing bispecific antibody treatments. Key targets include PRAME, DL3, GPC3, and p53. The experts emphasize the importance of achieving durable responses and using cell therapies as consolidation following first-line treatment. They also touch on the future of minimal residual disease (MRD)-guided therapies and the need for better assays in solid tumors. This discussion took place at the 7th International Workshop on CAR-T and bispecifics (iwCAR-T) 2025 held in Miami, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
